Jacob Sands, MD / Luis Paz-Ares, MD, PhD - Leveraging Precise Targets to Elevate Outcomes: NSCLC Treatment Strategies for HER2-Directed ADCs
CME in Minutes: Education in Oncology & Hematology11/15/24 • 26 min
Please visit answersincme.com/860/93496951-replay2 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in NSCLC discuss the clinical implications of the latest data for HER2-directed ADCs in NSCLC. Upon completion of this activity, participants should be better able to: Explain the rationale for antibody drug conjugates (ADCs) in the treatment of advanced non-small cell lung cancer (NSCLC); Identify the latest efficacy and safety data for ADCs in advanced NSCLC; Recognize key clinical factors to optimize the evidence-based use of current and emerging ADCs in advanced NSCLC; and Describe practical, data-driven approaches to effectively integrate current and emerging ADCs into the management of advanced NSCLC.
11/15/24 • 26 min
Generate a badge
Get a badge for your website that links back to this episode
Select type & size
<a href="https://goodpods.com/podcasts/cme-in-minutes-education-in-oncology-and-hematology-449630/jacob-sands-md-luis-paz-ares-md-phd-leveraging-precise-targets-to-elev-78338954"> <img src="https://storage.googleapis.com/goodpods-images-bucket/badges/generic-badge-1.svg" alt="listen to jacob sands, md / luis paz-ares, md, phd - leveraging precise targets to elevate outcomes: nsclc treatment strategies for her2-directed adcs on goodpods" style="width: 225px" /> </a>
Copy